Person:
YÜCEL, AHMET ALİ

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

YÜCEL

First Name

AHMET ALİ

Name

Filters

2019 - 201912020 - 20211
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Efficacy of dexamethasone implants in uveitic macular edema in cases with behcet disease
    (Karger, 2019-01-01) Yalçınbayır, Özgür; Çalışkan, Enver; Gündüz, Gamze Uçan; Gelişken, Öner; Kaderli, Berkant; Yücel, Ahmet Ali; YALÇINBAYIR, ÖZGÜR; Çalışkan, Enver; UÇAN GÜNDÜZ, GAMZE; YÜCEL, AHMET ALİ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göz Hastalıkları Anabilim Dalı; JAC-9459-2023; EQX-5743-2022; AAH-6661-2021; JYV-1141-2024
    Purpose: Investigation of the efficacy of intravitreal dexamethasone implants (0.7 mg) in patients with Behcet disease (BD) who had cystoid macular edema (CME) despite immunomodulatory treatment. Materials and Methods: Twenty-seven eyes of 20 patients who had intravitreal dexamethasone implant injections and follow-up for more than 6 months were included in this study. Best corrected visual acuities (BCVA), intraocular pressures (IOP), and central macular thicknesses (CMT) were recorded. Systemic immunomodulatory treatment was noted. Injection-related complications and the need for recurrent injections were recorded. Results: Statistically significant anatomical and functional success was achieved with a single injection. BCVA increased from 0.85 +/- 0.72 to 0.45 +/- 0.52 logMAR, while the mean CMT decreased from 406 +/- 190 to 243 +/- 101 mu m at the sixth month. The peak of visual acuity gain was reached within the first 2 months and a substantial proportion of the patients gained 3 or more lines. There was no complication other than transient IOP elevation in 4 eyes and cataract surgery in 2 eyes. Conclusion: Adjuvant intravitreal dexamethasone implant injections offer promising results in cases of BD with CME. It is effective in preserving the macular anatomy and vision particularly in transition to biological agents.
  • Thumbnail Image
    Publication
    Evaluation of choroidal thickness in children with type 1 diabetes: The role of optical coherence tomography in diabetic retinopathy screening
    (Japanese Soc Pediatric Endocrinology, 2021-01-01) Ermerak, Basak Can; Yalcinbayir, Ozgur; YALÇINBAYIR, ÖZGÜR; Eren, Erdal; EREN, ERDAL; Erseven, Cansu; Sobu, Elif; Yucel, Ahmet Ali; YÜCEL, AHMET ALİ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Oftalmoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji Anabilim Dalı.; 0000-0002-7311-5277; 0000-0002-1684-1053; JAC-9459-2023; AAH-6226-2021; IYJ-9408-2023; GSN-9730-2022; AAH-6625-2021
    The present study aimed to evaluate choroidal changes and alternations within the structure of the retina prior to visible morphologic signs of diabetic retinopathy (DR) in pediatric type 1 diabetes (T1D) cases. Two hundred and six eyes of 103 pediatric patients with T1D without DR and 88 eyes of 44 healthy controls were enrolled. They underwent a comprehensive ophthalmic examination and optical coherence tomography evaluation. Choroidal thickness (ChT) measurements were performed manually on macular and peripapillary regions. There was no significant difference between the two groups in terms of age, intraocular pressure, and axial length (p > 0.05). ChT measurements of subfoveal, nasal, and temporal macula were slightly thinner in the diabetic group, and no statistical significance was found (p = 0.835, p = 0.305, and p = 0.054, respectively). Peripapillary ChT of eight sectors were also thinner in T1D; however, superonasal, nasal, inferonasal, and inferior sector values were significantly different (p = 0.010, p = 0.020, p = 0.019, and p = 0.018, respectively). In conclusion; this study demonstrated evidence of peripapillary choroidal thinning in pediatric diabetic patients without visible signs of retinopathy.